

Journal Pre-proof

Decrease in acute periprosthetic joint infections incidence with vancomycin loaded calcium sulfate beads in patients with non-modifiable risk factors. A randomized clinical trial

Julio Carlos Vélez de Lachica, Senior researcher, Head in Orthopedics, Susana Serrano Reyes, Co-author, Fellowship of arthroscopy and joint surgery, Juan Antonio Pages Ureña, Co-author, Fellowship of arthroscopy and joint surgery, Miguel Angel Ruiz Fragoso, Co-Author, Fellowship of arthroscopy and joint surgery

PII: S2059-7754(22)00077-3

DOI: <https://doi.org/10.1016/j.jisako.2022.08.002>

Reference: JISAKO 48

To appear in: *Journal of ISAKOS*

Received Date: 13 December 2021


Revised Date: 28 June 2022

Accepted Date: 3 August 2022

Please cite this article as: Vélez de Lachica JC, Reyes SS, Pages Ureña JA, Ruiz Fragoso MA, Decrease in acute periprosthetic joint infections incidence with vancomycin loaded calcium sulfate beads in patients with non-modifiable risk factors. A randomized clinical trial, *Journal of ISAKOS*, <https://doi.org/10.1016/j.jisako.2022.08.002>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 The Author(s). Published by Elsevier Inc. on behalf of International Society of Arthroscopy, Knee Surgery and Orthopedic Sports Medicine.



Title: Decrease in acute periprosthetic joint infections incidence with vancomycin loaded calcium sulfate beads in patients with non-modifiable risk factors. A randomized clinical trial.

Clinical Trials: **NCT03976466** (clinicaltrials.gov)

Author names and affiliations.

- **Julio Carlos Vélez de Lachica. (Senior researcher)**

Head in Orthopedics Department at the Institute of Social Security of Mexican State and Districts. (ISSEMyM)

Phone number: 52 1 5518338063 email: activeknee@gmail.com

- **Susana Serrano Reyes (Co-author)**

Fellowship of arthroscopy and joint surgery email: ssusana.serranor@gmail.com

- **Juan Antonio Pages Ureña (Co-author)**

Fellowship of arthroscopy and joint surgery email: juan.pages1990@gmail.com

- **Miguel Angel Ruiz Fragoso (Co-Author)**

Fellowship of arthroscopy and joint surgery email: mike1889@gmail.com

Address: Avenida paseo del ferrocarril numero 88, Los reyes Ixtacala. Zip code

54055 ISSEMyM (Institution of Social Security of the Mexican State and Districts)

phone: 52 1 5526269200 ext 2100 2101

Corresponding author. Julio Carlos Vélez de Lachica email: activeknee@gmail.com

Manuscript word count:

- Abstract (278/300) words
- Text not including references (2359) words

TITLE: Decrease in acute periprosthetic joint infections incidence with vancomycin loaded calcium sulfate beads in patients with non-modifiable risk factors. A randomized clinical trial.

ABSTRACT

Objectives: The influence of local antibiotic therapy in orthopedic surgery remains unclear. In this trial, we evaluated the incidence of periprosthetic joint infections (PJI), after local or intravenous (IV) antibiotic prophylaxis. The aim of this intervention was to compare the PJI incidence in a population with non-modifiable risk factors after local prophylaxis with vancomycin loaded calcium sulfate beads versus a control group.

Methods: A total of 83 subjects were evaluated, inclusion criteria included participants over 60 years of age, with at least one main risk factor for PJI who underwent total hip or knee joint replacement between June 2019 and May 2020. Cases were randomized, the intervention group received local prophylactic antibiotic therapy with calcium sulfate beads impregnated with vancomycin; conventional IV prophylactic antibiotic therapy was administered for the control group. C reactive protein (CRP) and erythrocyte sedimentation rate (ERS) serum biomarkers were analyzed on day 5 and weeks 4, 8, and 12. When needed synovial fluid sample was obtained and cultured for the early acute PJI diagnosis.

Results: Acute PJI was found in 27 patients (67.5%) in the control group and 4 (9.3%) for the intervention group. Variable analysis identified that local prophylaxis with calcium sulfate beads reduce the incidence of acute knee or hip PJI in patients with non-modifiable risk factors compared to conventional prophylaxis ($p < 0.0001$) with a relative risk of 0.13 (CI:0.05-0.35). Length of hospital stay was also shorter in the intervention group at 4.6 days, compared to 15.25 days in the control group; $p < 0.001$.

Conclusions: Local antibiotic prophylaxis in patients with non-modifiable risk factors undergoing hip or knee replacement, reduces the incidence of acute PJI compared to IV antibiotics.

Level of Evidence: II

What are the new findings:

- Local antibiotic prophylaxis with vancomycin in patients with non modifiable risk factors decreases the incidence of periprosthetic joint infections compared to IV antibiotics.
- It is safe to apply calcium sulfate beads as antibiotic carrier at implant/bone interface.
- Decreasing the incidence of acute periprosthetic joint infections with local antibiotic prophylaxis using calcium sulfate beads reduces the length of hospital stay.

INTRODUCTION

Knee and hip joint replacement are some of the most recognized and successful orthopedic surgeries worldwide, however they are not exempt of complications; the most challenging and devastating one for the patient and physicians are periprosthetic joint infections (PJI)(1)(2). There are many important topics to evaluate for a PJI; non-modifiable risk factors may be influenced by the socio-economic status of the patients, becoming a challenge for physicians and having adverse effects on the economic burden of health institutes. It has been estimated that by the year 2030 more than \$1.85 billion will be spent in the U.S. on PJI and about 15,000 dollars per patient in México (3)(4). In México the demand of patients seeking health services exceeds the capacity of the Institutes, therefore making it impossible to adequately evaluate patients with a multidisciplinary approach before undergoing joint replacement. This leads physicians to use their own criteria and assess risks-benefits of joint replacement surgery, not only to improve the quality of life in patients, but also to allow them to resume their economic activities and avoid prolonged disability. However it has been proven that the joint replacement benefits far exceed the complications; this explains why, even though a patient could have one or more risk factors, the procedure is not contraindicated and remains the best option of treatment (5).

It has been proved that some patient co-morbidities are key factors in complications following total joint arthroplasty (TJA), leading to the identification of those risk factors in relation to PJI, as well as strategies to mitigate them. The choice of risk factors as inclusion criteria in this trial were according to a meta-analysis by Y. Zhu et al, who describes the main risk factors found in PJI (6) Table 1.

One important topic are the biomaterials used in arthroplasty, although biomedical implants such as joint prosthetics have revolutionized medicine, they also have an increased risk of infections, primarily caused by *Staphylococcus aureus* and secondly by *Staphylococcus epidermidis* (7)(8). Biofilm that forms on avascular zones, requires high concentrations of antibiotics and debridement to eliminate it. Sub-lethal antibiotic doses cause persistence and resistance of the infections, therefore methods to release antibiotics at the necessary concentrations locally and for a prolonged time have been sought (9). Polymethylmethacrylate (PMMA) has been used for years either as a bone cement spacer or as beads to carry antibiotic. However, it has been shown that PMMA does not eliminate biofilm, and 90% of the antibiotic remains trapped in the compound becoming more susceptible to bacterial colonization and biofilm formation (10).

To reduce the risk of periprosthetic infection, the application of local antibiotic at the surgical site may be a promising concept; for this purpose calcium sulfate beads have been used as a carrier, these begin to degrade within 4 to 8 weeks releasing antibiotic gradually over time, presenting minimal risk to damage the prosthesis components and having a low setting temperature which allows them to be mixed with thermo-sensitive antibiotics whereas PMMA cannot (11).

There are still not enough in vivo investigation reports on the use of calcium sulfate in prosthetic implants (11)(12). A randomized controlled trial in patients with non-modifiable risk factors for PJI was performed, comparing the intervention group where prophylactic local calcium sulfate impregnated with vancomycin was applied versus a control group with a standard IV antibiotic prophylaxis. We hypothesized that the incidence of acute PJI and hospital length of stay would be lower in the intervention group compared to the control group.

METHODS

Trial Design

A prospective, longitudinal and randomized controlled trial was designed. The intervention was performed at the department of Orthopedics in our Institution and approved by the ethics and research committee.

Participants

The eligibility criteria for this intervention were: being over 60 years of age, having one or more non-modifiable risk factors, patients who underwent total hip or knee joint replacement between June 2019 and May 2020. The exclusion criteria were: patients with an active systemic infection, kidney or liver failure, known allergies to vancomycin or cephalosporin (8)(6).

Outcomes

Our primary outcome was to determine the relationship between antibiotic prophylaxis with local calcium sulfate beads in patients with non-modifiable risk factors for PJI and its clinical progress with or without infection, compared with a standard antibiotic prophylaxis control group. The secondary outcome was to determine if there was an improvement in hospital length stay, which could be translated into a lower rate of economic burden.

Sample Size

According to our biostatistics department records, in 2018 a total of 354 knee and hip arthroplasties were performed. Out of the total procedures, 94 had one or more non-modifiable risk factor (8)(6). This population were used for the sample size determination, with a desired 95% confidence level and a maximum acceptable error percentage of 5 %. These data were calculated (STATS 2.0 Software) and a minimum number of participants were 76 to obtain a statistically significant different p value. At the enrollment period we obtained 87 participants, 4 of whom were excluded due to expiration of health insurance ending with a total of 83.

Blinding and Randomization

All participants who met the selection criteria were invited to be part of the intervention, detailing that they will not know which group they would be in, and could have a systemic or local prophylactic therapy according to the group randomly assigned (Randomizer v.0.2.6.). Once the ethics and procedures of the research were explained, the participants signed a letter of informed consent agreeing to join the randomized clinical trial.

Study Participants

Subjects enrolled in the control group received a prophylactic intravenous cefuroxime dose of 750 mg, 20 minutes before joint replacement surgery and every 8 hours for 24 hours.

Regarding the patients assigned to the intervention group, none received parenteral antibiotic prophylaxis. In the operating room and before the final implantation of the prosthesis, the

commercially pure calcium sulfate beads were impregnated with 3g of vancomycin and applied locally. For the local prophylaxis we utilized a Stimulan Kit (Biocomposites Ltd, United Kingdom)(12); which includes 10 cc (20g) of calcium sulfate hemihydrate powder, a pre-mixing solution bulb, mold of 3, 4.8 and 6 mm sizes of beads and spatula. 3g of vancomycin powder was mixed with each 10 cc of calcium sulfate in the mixing bowl, after 30 seconds the resulting paste was applied to the molds using the spatula and allowing to set for 10 to 15 minutes. In the hip joint the 3 mm beads were pulverized and applied on the previously reamed acetabular cavity. For the proximal femur, the beads were inserted into the medullary canal and the final components were placed by impaction, ending the placement of the beads at the interface zones. The remaining beads were applied to the soft tissue around the prosthesis. For the knee joint, the 4.8mm beads were applied inside the femoral and tibial medullary canals (Fig. 1), the remaining beads were placed into the soft tissue around the prosthesis before cementation (Fig 2). Antibiotic loaded PMMA was not used in any subject.

After surgery, the acute PJI diagnosis algorithm was established in accordance to Della Valle, Jarvad Parvizi, et al, clinical practice guideline by measuring acute phase reactants, cell count and synovial culture; C reactive protein (CRP) and erythrocyte sedimentation rate (ESR) biomarkers were analyzed on day 5 and weeks 4, 8, and 12 for acute periprosthetic infection. A CRP > 93mg/L and ESR >44mm/hr. were considered the cutoff value for infection risk (13). If CRP was elevated alone or with ESR, then a synovial fluid sample was obtained and analyzed. A threshold of leukocytes >12,800 cells/ μ L and/or a positive culture was defined as an acute periprosthetic joint infection (14)(15).

Statistical analysis

Statistical analysis was performed using SPSS Statistics 26 IBM software. Prospectively recorded data included: patient demographics; biomarkers values before and after surgery, diagnosis and kind of arthroplasty replacement, non-modifiable risk factors for PJI, synovial fluid analysis and length of hospital stay. The presence of periprosthetic infection in both groups was evaluated by two-sided Chi² and Fisher's exact tests for dichotomous nominal and qualitative variables with longitudinal direction and Relative Risk test; Cramer's V test was analyzed to assess the strength of relationship between variables. Length of hospital stay

and continuous data with normal or skewed distribution were reported as mean (and SD) and median respectively, Student's *t*-test and Mann-Whitney U test were used for independent continuous variables. A two-tailed α value <0.05 was set as significant.

RESULTS

A total of 87 subjects were enrolled in the period between June 2019 to May 2020, four of them were excluded (the Institutional insurance of the four patients expired, therefore no postoperative follow-up was obtained). The remaining 83 patients were evaluated, 44 cases were female (53%) and 39 cases were male (46.9%). The mean age were 76.6 (61 to 90) years old. BMI was the main risk factor found (19.28%) followed by uncontrolled diabetes mellitus type 2 (18.07%). All the patients had at least one main risk factor for presenting periprosthetic infection (Table 2). Although both knee and hip prostheses were placed, differences between these were not considered because of a small sample size. A total of 38 knees were placed (52.5% for control group versus 39.5% for the intervention group) and 45 hips were treated (47.5% and 60.5% for control and intervention groups respectively). There was no difference in demographic variables for either treatment group ($p>0.05$)

The subjects were randomly assigned in two groups for the longitudinal design intervention. Forty subjects (48%) were enrolled for the control group and received standard IV prophylactic antibiotic therapy with cephalosporin for a total of 24 hours. For the intervention group, 43 patients (51.8%) received local antibiotic therapy with calcium sulfate beads mixed with vancomycin during the surgery. Although prophylactic treatment was supplied in both groups, the presence of early periprosthetic infection was found in 37.3%. Acute PJI was found in 27 subjects (67.5%) enrolled in the control group while 4 (9.3) were found in the study group.

All 31 participants with acute PJI had a positive synovial fluid culture. According to the analysis of presence or absence of PJI we identified that local prophylaxis with calcium sulfate beads compared to standard prophylaxis can further prevent the presence of acute knee or hip periprosthetic infection in patients with non-modifiable risk factors ($p=0.0001$)

with a 0.13 of relative risk C.I. (0.05-0.33). The incidence of acute periprosthetic joint infection is 87% less in patients with local prophylaxis with calcium sulfate beads impregnated with vancomycin than those with standard prophylaxis (Table 3). Length of stay was also shorter in the intervention group at 4.6 days (range: 2-23 days) compared to 15.25 days in the control group (range: 2-32 days; $p < 0.001$) (Table 4)

DISCUSSION

The present study provides information that local antibiotic prophylaxis may have a greater influence on the prevention of acute PJI in patients with non-modifiable risk factors. Nevertheless there were some limitations, the first one is that this study only evaluates acute joint infections from postoperative to 3 months and no cases of chronic infection were considered. Another limitation was that the guidelines for PJI diagnosis could not be followed using biomarkers like d-dimer, Alpha-defensin, and histologic analysis (15). Therefore, the diagnosis was made by CRP and ESR biomarkers, synovial white blood cell count and culture. In our country the socio-cultural conditions of the population do not allow adequate knowledge of diseases, leading to underestimation of repercussions on their health conditions due to poor adherence in their treatments. We have found in this study, that some patients who require surgical joint replacement treatment do not have adequate control of their chronic conditions, increasing the risk of infection by having risk factors that cannot be modified in the short or medium term (16). Although adequate preoperative preparation is mandatory, in our population it is not feasible to control all the risk factors because of our socio-cultural environment (4). Despite this, in many cases replacement surgery is necessary to provide a better quality of life (5). During the trial 367 arthroplasties were carried out including primary and revisions, 280 of them did not comply with the eligibility criteria, therefore 83 participants with non-modifiable risk factors for PJI risk were enrolled. Once the acute infection has been diagnosed, the treatment that follows is complex and not without complications; in patients who also have risk factors or active diseases treatment, becomes even more difficult and expensive (2).

In previous years we found that the prevalence of PJI in our Institution were very high compared with the international references, for this reason we initiated protocols to reduce this prevalence found among some procedures, like local application of antibiotics which has

been studied on several occasions (17). However direct application to the prosthetic bone interface areas, has not yet been well established. In the present research, we were able to identify that the application of a local antibiotic in contact with the prosthetic components and surrounding tissue is beneficial for patients. Periprosthetic infections will continue to be an issue with devastating consequences for the patient, the surgeon, and the health system.

Similar findings were reported by Parvizi et al. showing that one of the greatest challenges in PJI prevention is risk factor recognition, whether modifiable or non-modifiable. Recognition of these factors will allow us to focus on better prevention strategies (18). Michael M. Kheir et al. have also published the relationship between risk factors and the increased susceptibility to infection, as well as antibiotic prophylaxis, their study demonstrates that extended oral antibiotic prophylaxis by 7 days postoperatively may reduce the prevalence of infection by counteracting poor host factors up to 1 year (19). The present study found that medicated calcium sulfate beads as a local release method of prophylactic antibiotic therapy, has the potential to reduce PJI in patients with non-modifiable risk factors by 86.6% as well as their associated complications and economic burden, however more studies are required to corroborate long term results.

CONCLUSIONS

Antibiotic loaded calcium sulfate beads as a local antibiotic prophylaxis method in patients with non-modifiable risk factors undergoing hip or knee replacement provide adequate protection, reduce the risk of presenting an acute periprosthetic joint infection and shortening the length of hospital stay.

REFERENCES:

1. Khanduja V. Total Hip Arthroplasty in 2017 - Current Concepts and Recent Advances. *Indian J Orthop* [Internet]. 2017;51(4):357–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/28790463>
2. Pierce AZ, Menendez ME, Tybor DJ, Salzler MJ. Three different databases, three different complication rates for knee and hip arthroplasty: comparing the National

- Inpatient Sample, National Hospital Discharge Survey, and National Surgical Quality Improvement Program, 2006 to 2010. *JAAOS-Journal Am Acad Orthop Surg*. 2019;27(12):e568–76.
3. Premkumar A, Kolin DA, Farley KX, Wilson JM, McLawhorn AS, Cross MB, et al. Projected Economic Burden of Periprosthetic Joint Infection of the Hip and Knee in the United States. *J Arthroplasty* [Internet]. 2021;36(5):1484-1489.e3. Available from: <https://www.sciencedirect.com/science/article/pii/S0883540320312444>
 4. Barrera-Cruz A, Rodríguez-González A, Molina-Ayala MA. The current state of obesity in Mexico Escenario actual de la obesidad en México. Vol. 51, *Rev Med Inst Mex Seguro Soc*. 2013.
 5. Boyce L, Prasad A, Barrett M, Dawson-Bowling S, Millington S, Hanna SA, et al. The outcomes of total knee arthroplasty in morbidly obese patients: a systematic review of the literature. *Arch Orthop Trauma Surg* [Internet]. 2019;139(4):553–60. Available from: <https://doi.org/10.1007/s00402-019-03127-5>
 6. Zhu Y, Zhang F, Chen W, Liu S, Zhang Q, Zhang Y. Risk factors for periprosthetic joint infection after total joint arthroplasty: A systematic review and meta-analysis [Internet]. Vol. 89, *Journal of Hospital Infection*. W.B. Saunders Ltd; 2015 [cited 2020 Jul 17]. p. 82–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/25575769/>
 7. Rohde H, Burandt EC, Siemssen N, Frommelt L, Burdelski C, Wurster S, et al. Polysaccharide intercellular adhesin or protein factors in biofilm accumulation of *Staphylococcus epidermidis* and *Staphylococcus aureus* isolated from prosthetic hip and knee joint infections. *Biomaterials* [Internet]. 2007;28(9):1711–20. Available from: <https://www.sciencedirect.com/science/article/pii/S014296120601012X>
 8. Maoz G, Phillips M, Bosco J, Slover J, Stachel A, Inneh I, et al. The Otto Aufranc Award: Modifiable versus Nonmodifiable Risk Factors for Infection After Hip Arthroplasty. *Clin Orthop Relat Res* [Internet]. 2015;473(2):453–9. Available from: <https://doi.org/10.1007/s11999-014-3780-x>
 9. van Vugt TAG, Arts JJ, Geurts JAP. Antibiotic-Loaded Polymethylmethacrylate Beads and Spacers in Treatment of Orthopedic Infections and the Role of Biofilm Formation. *Front Microbiol*. 2019;10(July):1–11.
 10. Kelm J, Regitz T, Schmitt E, Jung W, Anagnostakos K. In vivo and in vitro studies

- of antibiotic release from and bacterial growth inhibition by antibiotic-impregnated polymethylmethacrylate hip spacers. *Antimicrob Agents Chemother.* 2006;50(1):332–5.
11. Aiken SS, Cooper JJ, Florance H, Robinson MT, Michell S. Local Release of Antibiotics for Surgical Site Infection Management Using High-Purity Calcium Sulfate: An In Vitro Elution Study. *Surg Infect (Larchmt)*. 2015;16(1):54–61.
 12. Abosala A, Ali M. The Use of Calcium Sulphate beads in Periprosthetic Joint Infection, a systematic review. *J Bone Jt Infect.* 2020;5(1):43–9.
 13. Yi PH, Cross MB, Moric M, Sporer SM, Berger RA, Della Valle CJ. The 2013 frank stinchfield award: Diagnosis of infection in the early postoperative period after total hip arthroplasty. *Clin Orthop Relat Res.* 2014;472(2):424–9.
 14. Valle CD, Parvizi J, Bauer TW, DiCesare PE, Evans RP, Segreti J, et al. Diagnosis of periprosthetic joint infections of the hip and knee. *J Am Acad Orthop Surg.* 2010;18(12):760–70.
 15. Shohat N, Bauer T, Buttaro M, Budhiparama N, Cashman J, Della Valle CJ, et al. Hip and Knee Section, What is the Definition of a Periprosthetic Joint Infection (PJI) of the Knee and the Hip? Can the Same Criteria be Used for Both Joints?: Proceedings of International Consensus on Orthopedic Infections. *J Arthroplasty.* 2019;34(2):S325–7.
 16. Iorio R, Williams KM, Marcantonio AJ, Specht LM, Tilzey JF, Healy WL. Diabetes Mellitus, Hemoglobin A1C, and the Incidence of Total Joint Arthroplasty Infection. *J Arthroplasty [Internet]*. 2012;27(5):726-729.e1. Available from: <https://www.sciencedirect.com/science/article/pii/S0883540311005067>
 17. Vélez-de Lachica JC, Santos-Briones JI I-SJ. Aplicación profiláctica de sulfato de calcio medicado en prótesis total de cadera no cementada. *Acta Ortop Mex [Internet]*. 2019;33(2):67–72. Available from: <https://www.medigraphic.com/pdfs/ortope/or-2019/or192b.pdf>
 18. Alijanipour P, Heller S, Parvizi J. Prevention of periprosthetic joint infection: what are the effective strategies? *J Knee Surg.* 2014 Aug 1;27(4):251–8.
 19. Kheir MM, Dilley JE, Ziemba-Davis M, Meneghini RM. The AAHKS Clinical Research Award: Extended Oral Antibiotics Prevent Periprosthetic Joint Infection in

High-Risk Cases: 3855 Patients With 1-Year Follow-Up. J Arthroplasty. 2021 Jul 1;36(7):S18–25.

Journal Pre-proof

Table 1. Risk factors for preriposthetic joint infection

Risk Factor	
BMI	>40 kg/m ²
Diabetes Mellitus	> 7 % HbA1c
Nosocomial infection	Yes / No
Albumin in blood	< 3 g/dl
Immunosuppression	Yes / No
Malignancy	Yes / No
Steroid therapy	Yes / No
Rheumatoid Arthritis	Yes / No
Active wound infection	Yes / No
History of joint arthroplasty	Yes / No
Excessive surgical bleeding	Blood transfusion indication Yes / No
Operative time	(> 120 min)
BMI, Body mass index; HbA1c, Glycosilated hemoglobin test	

Table 2. Demographics and Non Modifiable risk factors				
Parameter / Group	Standard Prophylaxis	Local Prophylaxis	TOTAL	P value
Demographics				
Age (mean ± SD)	77.3 ± 8.94	75.9 ± 8.14	76.6 ± 8.51	0.41
Gender	(%)	(%)		0.72
Female	22 (55.0)	22 (51.2)	44 (53%)	
Male	18 (45.0)	21 (48.8)	39 (47%)	
Joint				0.23
Hip	19 (47.5)	26 (60.5)	45 (54.3%)	
Knee	21 (52.5)	17 (39.5)	38 (45.7%)	
Non modifiable risk factors for PJI				
Preoperative				
BMI	6 (15%)	10 (23.2%)	16 (19.2%)	0.41
History of nosocomial infection	3 (7.5%)	3 (6.9%)	6 (7.2%)	0.99
Decompensated Diabetes Mellitus	7 (17.5%)	8 (18.6%)	15 (18%)	0.99
Serum albumin	4 (10%)	1 (2.3%)	5 (6.0%)	0.19
Immunosuppression	1 (2.5%)	0	1 (1.2%)	0.48
Malignancy	0	3 (6.9%)	3 (3.6%)	0.24
Steroid therapy	0	1 (2.3%)	1 (1.20%)	0.99
Rheumatoid arthritis	5 (12.5%)	2 (4.6%)	7 (8.4%)	0.25
Active wound infection at a distant zone	4 (10%)	2 (4.6%)	6 (7.2%)	0.42
History of joint arthroplasty	1 (2.5%)	3 (6.9%)	4 (4.8%)	0.61
During operative time				
Excessive surgical bleeding	5 (12.5%)	7 (16.2%)	12 (14.4%)	0.75
Prolonged operative time	4(10%)	3 (6.9%)	7 (8.4%)	0.70

Table 3. Acute PJI comparison for patients underwent standard versus local antibiotic prophylaxis. Leucocytes were measure only in patients with elevated CRP and ESR.

	Periprosthetic Joint Infection				Without Periprosthetic Joint infection				p Value
TOTAL	31(37.3%)				52(62.7%)				<0.001
	Standard Group n=40		Local group n=43		Standard Group n=40		Local group n=43		
	27(67.5%)		4(9.3%)		13(32.5%)		39(90.7%)		<0.001
	Knee	Hip	Knee	Hip	Knee	Hip	Knee	Hip	
CRP	84.64 ± 14.3	93.53 ± 14.6	77.85 ± 14.9	77.45 ± 18.0	32.57 ± 42.5	16.21 ± 9.5	17.38 ± 17.5	21.4 ± 22.1	
ERS	45.29 ± 5.6	48.7 ± 5.2	46.0 ± 2.8	52.5 ± 5.2	26.25 ± 7.9	25.8 ± 10.8	20.06 ± 7.9	20.04 ± 10.8	
LEUCOCYTES	6682.3 ± 3776.9 (17)	6570 ± 2852.6 (10)	4750 ± 70.7 (2)	8950 ± 6434.6 (2)	- (0)	- (0)	1300 ± 0 (1)	1590 ± 1404.8 (4)	

Table 4. Days of Hospital Stay				
Length of Hospital stay				
	Standard group n=40	Local group n= 43	Total n= 83	p Value
Hip	15.15 ± 10.70	4.15 ± 3.49	8.80 ± 9.16	
Knee	15.33 ± 9.71	5.47 ± 5.99	10.92 ± 9.55	
TOTAL:	15.25 ± 10.06	4.67 ± 4.62	9.77 ± 9.34	<0.0001



Journal



Journal Pre-proof